# NCT07365995 (NCT07365995)

> A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07365995
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: BioNTech SE
- Conditions: Metastatic Castration-resistant Prostate Cancer
- Interventions: BNT324; Docetaxel; Prednisone/prednisolone
- Enrollment: 736
- Primary outcome: rPFS assessed by BICR
- Primary outcome: OS

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct07365995